Antibody that binds to anti-HIV-1 V3 antibody 1C10(0.5γ) and its antigen-binding fragment, and applications thereof

Anti-idiotype antibodies are developed to accurately measure anti-HIV-1 V3 antibody 1C10 (0.5γ) in human samples, addressing the inaccuracy of existing methods and improving treatment monitoring for HIV-1 infection.

JP7595249B2Active Publication Date: 2024-12-06NAT UNIV CORP KUMAMOTO UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021551277
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-09-30
Filing Date
2020-09-29
Publication Date
2024-12-06
Estimated Expiration
2040-09-29

AI Technical Summary

Technical Problem

Current methods for measuring the blood concentration of anti-HIV-1 V3 antibody 1C10 (0.5γ) in humans are inadequate due to the induction of anti-HIV-1 antibodies other than 1C10, leading to inaccurate quantification.

Method used

Development of anti-idiotype antibodies that specifically bind to anti-HIV-1 V3 antibody 1C10 (0.5γ), allowing for the creation of detection agents and methods to accurately detect and quantify the antibody in human samples using techniques like ELISA and electrochemiluminescence assays.

Benefits of technology

Enables precise detection and quantification of anti-HIV-1 V3 antibody 1C10 (0.5γ) in human samples, enhancing the monitoring of treatment effectiveness for HIV-1 infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595249000006
    Figure 0007595249000006
  • Figure 0007595249000007
    Figure 0007595249000007
  • Figure 0007595249000008
    Figure 0007595249000008
Patent Text Reader

Abstract

The present invention addresses the problem of providing an antibody against anti-HIV-1 V3 antibody 1C10(0.5γ) and a method for specifically detecting anti-HIV-1 V3 antibody 1C10(0.5γ). The preset invention provides an antibody that binds to anti-HIV-1 V3 antibody 1C10(0.5γ) or an antigen-binding fragment thereof. The preset invention provides an agent for detecting anti-HIV-1 V3 antibody 1C10(0.5γ), said agent comprising an antibody that binds to anti-HIV-1 V3 antibody 1C10(0.5γ) or an antigen-binding fragment thereof. The preset invention provides a method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample. The preset invention provides a method for determining the concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample. The preset invention provides a method for judging or monitoring the efficacy of a therapy using anti-HIV-1 V3 antibody 1C10(0.5γ) on an HIV patient.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to antibodies and antigen-binding fragments thereof which bind to the anti-HIV-1 V3 antibody 1C10(0.5γ). The present invention relates to a detection agent for the anti-HIV-1 V3 antibody 1C10(0.5γ). The present invention relates to a method for detecting the anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample. The present invention relates to a method for determining the concentration of the anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample. The present invention further relates to a method for assessing or monitoring the effectiveness of treatment with the anti-HIV-1 V3 antibody 1C10(0.5γ) in a subject suffering from HIV-1 infection. CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to Japanese Patent Application No. 2019-180305, filed September 30, 2019, the entire disclosure of which is expressly incorporated herein by reference. [Background technology]

[0002] Human immunodeficiency virus-1 (HIV-1) infects CD4-positive lymphocytes and other cells, gradually destroying them and causing acquired immunodeficiency syndrome (AIDS) / HIV-1 infection. Advances in antiviral therapy (e.g., combination antiretroviral therapy (cART)) have significantly improved the prognosis of HIV-1 infection, but it is not curable and antiviral therapy remains a lifelong treatment.

[0003] Meanwhile, development of a treatment for HIV-1 infection using neutralizing antibodies is underway. In the immune response to HIV-1 infection, HIV-1-specific antibodies are produced, and HIV-1 infection can be diagnosed by the presence or absence of such antibodies. HIV-1-specific antibodies include neutralizing antibodies that can bind to viral particles and inhibit viral infectivity. For example, Matsushita S, et al (Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS 29: 453-462, 2015) (the entire disclosure of which is incorporated herein by reference) reports cases in which humanized anti-HIV-1 monoclonal antibody KD-247 reduced the viral load in patients with chronic HIV-1 infection and maintained a stable viral load in clinical trials.

[0004] Most of the neutralizing antibodies isolated so far are strain-specific, meaning that they can neutralize a particular HIV-1 strain but not other HIV-1 strains with different amino acid sequences. However, some antibodies are known to neutralize a broad range of HIV-1 strains, and these neutralizing antibodies recognize the V3 loop and CD4 binding site of the viral envelope. WO2009 / 066702 (Patent Publication No. 5526386) (the entire disclosure of which is incorporated herein by reference) discloses a monoclonal antibody 1C10(0.5γ) that recognizes the V3 loop of the envelope glycoprotein of the HIV-1 virus, and it has been reported that this 1C10(0.5γ) is an antibody that neutralizes a wider range of HIV-1 virus strains than KD-247 (Ramirez, K, et al: Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains. Virology, 475, 187-203, 2015.doi:10.1016 / j.virol.2014.11.011) (the entire disclosure of which is incorporated herein by reference).

[0005] A large-scale expression system for the anti-HIV-1 V3 antibody 1C10(0.5γ) has been established, and a proof-of-concept (POC) study to demonstrate its efficacy has been started in non-human primates. In a POC study using the anti-HIV-1 V3 antibody 1C10(0.5γ) as a treatment for HIV-1 infection, a correlation was observed between the neutralizing effect in SHIV (simian-human immunodeficiency virus)-infected individuals and the blood concentration of the anti-HIV-1 V3 antibody 1C10(0.5γ), and therapeutic effects in humans are expected. Summary of the Invention [Problem to be solved by the invention]

[0006] In non-human primate models, it was revealed that the neutralizing effect of the anti-HIV-1 V3 antibody 1C10(0.5γ) correlates with its blood concentration, so it is thought that measurement of the blood concentration of the anti-HIV-1 V3 antibody 1C10(0.5γ) in patients administered the anti-HIV-1 V3 antibody 1C10(0.5γ) will be important in human clinical trials as well. Currently, the blood concentration of the anti-HIV-1 V3 antibody 1C10(0.5γ) is measured by EIA (enzyme immunoassay) using the V3 peptide as an antigen. However, in non-human primate models, anti-HIV-1 V3 antibodies are not induced, so the above method can measure the blood concentration of anti-HIV-1 V3 antibody 1C10(0.5γ). However, in human cases of HIV-1 infection, there are cases in which anti-HIV-1 V3 antibodies other than 1C10(0.5γ) are induced, so the above method is insufficient to accurately measure the blood concentration of anti-HIV-1 V3 antibody 1C10(0.5γ).

[0007] Therefore, an object of the present invention is to provide an antibody against the anti-HIV-1 V3 antibody 1C10(0.5γ) and a method for specifically detecting the anti-HIV-1 V3 antibody 1C10(0.5γ). [Means for solving the problem]

[0008] As a result of intensive research aimed at solving the above problems, the present inventors developed multiple anti-idiotype antibodies against the anti-HIV-1 V3 antibody 1C10(0.5γ), and further succeeded in specifically detecting the anti-HIV-1 V3 antibody 1C10(0.5γ) using these anti-idiotype antibodies. The present invention was completed based on the above findings.

[0009] According to the present invention, the following inventions are provided. [1] An antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) (anti-1C10(0.5γ) antibody) or an antigen-binding fragment thereof, a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; c) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively; d) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 19, 20, and 21, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23, and 24, respectively; or e) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 28, 29, and 30, respectively; The anti-HIV-1 V3 antibody 1C10(0.5γ) comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 41 and 42, respectively, or an antigen-binding fragment thereof. [2] The heavy chain variable region and the light chain variable region of the anti-1C10(0.5γ) antibody are a) SEQ ID NOs: 31 and 32; b) SEQ ID NOs: 33 and 34; c) SEQ ID NOs: 35 and 36, d) SEQ ID NOs: 37 and 38, or e) SEQ ID NOs: 39 and 40 The anti-1C10(0.5γ) antibody or antigen-binding fragment thereof according to [1], each of which contains an amino acid sequence that is at least 80% identical to the amino acid sequence described in [3] The anti-1C10(0.5γ) antibody or its antigen-binding fragment according to [1] or [2], wherein the anti-1C10(0.5γ) antibody is a full-length IgG antibody. [4] The antigen-binding fragment is a Fab fragment, F(ab') 2 The anti-1C10(0.5γ) antibody or the antigen-binding fragment thereof according to any one of [1] to [3], which is a fragment, an Fv fragment, or an scFv fragment. [5] The anti-1C10(0.5γ) antibody or an antigen-binding fragment thereof according to any one of [1] to [4], which recognizes the antigen recognition region of the anti-HIV-1 V3 antibody 1C10(0.5γ). [6] A nucleic acid encoding any one of the anti-1C10(0.5γ) antibodies or antigen-binding fragments thereof described in any one of [1] to [5]. [7] An expression vector comprising the nucleic acid described in [6]. [8] A transformant comprising the expression vector described in [7]. [9] A detection agent for the anti-HIV-1 V3 antibody 1C10(0.5γ), comprising any one of the anti-1C10(0.5γ) antibodies or antigen-binding fragments thereof described in any one of [1] to [5].

[10] A method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample, comprising: contacting the sample with any one of the anti-1C10(0.5γ) antibodies or antigen-binding fragments thereof described in any one of [1] to [5]; and detecting the anti-HIV-1 V3 antibody 1C10(0.5γ) bound to the anti-1C10(0.5γ) antibody or antigen-binding fragment thereof according to any one of the above [1] to [5] Includes, a method.

[11] The method according to

[10] , wherein the detection is performed by a sandwich assay.

[12] The method according to

[10] or

[11] , wherein the detection is by enzyme-linked immunosorbent assay (ELISA) or electrochemiluminescence assay.

[13] The method according to

[11] or

[12] , wherein the capture antibody in the sandwich assay is any one of the anti-1C10(0.5γ) antibodies and antigen-binding fragments thereof described in any one of [1] to [5], and the detection antibody in the sandwich assay is any one of the anti-1C10(0.5γ) antibodies and antigen-binding fragments thereof described in any one of [1] to [5].

[14] The above capture antibody a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; or b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; and wherein the antibody or antigen-binding fragment thereof comprises The above detection antibody a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; or b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; an antibody or antigen-binding fragment thereof comprising The method described in

[13] .

[15] A method for determining the concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample, comprising: determining the concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample by using the detection method according to any one of

[10] to

[14] . A method comprising:

[16] A method for determining or monitoring the effectiveness of treatment with anti-HIV-1 V3 antibody 1C10(0.5γ) in a subject suffering from HIV-1 infection, comprising: determining a level of the anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample from a subject to which the anti-HIV-1 V3 antibody 1C10(0.5γ) has been administered in advance, using the detection method according to any one of

[10] to

[14] ; and A method comprising the step of comparing the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a control sample with the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample from a subject. Effect of the Invention

[0010] According to the present invention, it is possible to provide an antibody that binds to anti-HIV-1 V3 antibody 1C10(0.5γ) and an antigen-binding fragment thereof. According to the present invention, it is possible to provide a detection agent for anti-HIV-1 V3 antibody 1C10(0.5γ). According to the present invention, it is possible to provide a method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample. According to the present invention, it is possible to provide a method for determining the concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample. According to the present invention, it is possible to provide a method for determining or monitoring the effectiveness of treatment with anti-HIV-1 V3 antibody 1C10(0.5γ) in an HIV patient. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 shows the heavy chain amino acid sequences (sequence numbers 31, 33, 35, 37, and 39) of five anti-1C10 idiotype antibody clones (#87, #92, #102, #103, and #G46). [Diagram 2] FIG. 2 shows the light chain amino acid sequences (sequence numbers 32, 34, 36, 38, and 40) of five anti-1C10 idiotype antibody clones (#87, #92, #102, #103, and #G46). [Figure 3A]FIG. 3A is an explanatory diagram of ELISA for measuring the inhibitory activity of anti-1C10 idiotype antibodies (Anti-Id Abs) on the binding of 1C10 to V3 peptide (JRFL NNT20). [Figure 3B] Figure 3B shows the results of measuring the 1C10 binding inhibitory activity by ELISA. The anti-1C10 idiotypic antibodies (#87, #92, #102, #103, and #G46) showed no cross-reactivity with the five anti-HIV-1 V3 antibodies other than 1C10, namely, KD-247, 5G2, 1D9, 717G2, and 19F8. The "□" (white square) in the graph indicates a positive control in which unlabeled 1C10 inhibits the binding of biotinylated 1C10 (1C10-biotin in Figure 3A) or other biotinylated anti-HIV-1 V3 antibodies. [Figure 4A] FIG. 4A shows the positions of primers used in overlap PCR to generate 1C10 germline reverted mutants. [Figure 4B] FIG. 4B is a schematic diagram of 1C10 germline reverted mutants. [Diagram 5] FIG. 5 shows the results of ELISA analysis of the binding activity of anti-idiotypic antibodies to 1C10 mutants. [Figure 6] FIG. 6 shows an example of a method for diluting a sample using an ELISA microplate in an embodiment. [Figure 7] FIG. 7 is a schematic diagram of sandwich ELISA. [Figure 8] FIG. 8 shows the results of detection of 1C10 by sandwich ELISA using anti-idiotype antibodies Fab and IgG. [Figure 9] FIG. 9 shows the results of 1C10 detection in which the Fab of any one of five types of anti-idiotype antibodies was coated on a microplate as a solid-phase antibody (capture antibody) and biotinylated IgG of anti-idiotype antibody #87 was used as a detection antibody. [Figure 10]FIG. 10 shows the results of 1C10 detection using #92 Fab as the solid-phase antibody and #87 biotinylated IgG as the detection antibody; the results of 1C10 detection using #87 Fab as the solid-phase antibody and #87 biotinylated IgG as the detection antibody; and the results of 1C10 detection using #87 Fab as the solid-phase antibody and #92 biotinylated IgG as the detection antibody. [Figure 11A] FIG. 11A shows the results of Biacore (registered trademark) analysis (sensorgram) to evaluate the binding activity of anti-1C10 idiotype antibody #87 to 1C10. [Figure 11B] FIG. 11B shows the results of Biacore (registered trademark) analysis (sensorgram) to evaluate the binding activity of anti-1C10 idiotype antibody #92 to 1C10. [Figure 11C] FIG. 11C shows the results of Biacore (registered trademark) analysis (sensorgram) to evaluate the binding activity of anti-1C10 idiotype antibody #102 to 1C10. [Figure 11D] FIG. 11D shows the results of Biacore (registered trademark) analysis (sensorgram) to evaluate the binding activity of anti-1C10 idiotype antibody #G46 to 1C10. [Figure 12] FIG. 12 shows the heavy chain variable region (SEQ ID NO: 41) and light chain variable region (SEQ ID NO: 42) of the anti-HIV-1 V3 antibody 1C10 (0.5γ), which recognizes the V3 loop of the HIV-1 viral envelope glycoprotein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] The following description of the present invention may be based on representative embodiments and specific examples, but the present invention is not limited to such embodiments. In this specification, a numerical range expressed using "~" means a range including the numerical values ​​before and after "~" as the lower and upper limits.

[0013] (Antibody or antigen-binding fragment thereof that binds to anti-HIV-1 V3 antibody 1C10(0.5γ)) The anti-HIV-1 V3 antibody 1C10 (0.5γ) is disclosed in Japanese Patent No. 5,526,386, and is an antibody that recognizes the V3 loop of the envelope glycoprotein of the HIV-1 virus, and comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 41 and 42, respectively ( FIG. 12 ). In addition to 1C10 (0.5γ), other anti-HIV-1 V3 antibodies include KD247 and 5G2 disclosed in Japanese Patent No. 5526386, 1D9 and 717G2 described in Ramirez, K, et al., 2015 (supra), and 19F8 described in Mohammad Mamun Alam et al., (2019). Synergistic inhibition of cell-to-cell HIV-1 infection by combinations of single chain variable fragments and fusion inhibitors. Biochemistry and biophysics reports. 20. 100687. 10.1016 / j.bbrep.2019.100687. (the entire contents of which are incorporated herein by reference).

[0014] The antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention is an antibody that specifically recognizes the anti-HIV-1 V3 antibody 1C10(0.5γ), and in particular can recognize the antigen recognition region of 1C10(0.5γ). The anti-HIV-1 V3 antibody 1C10(0.5γ) can be specifically detected using the antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention. The anti-HIV-1 V3 antibody 1C10(0.5γ) can be specifically and quantitatively detected using the antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention.

[0015] In the present specification, an antibody has a structure in which two heavy chains (H chains) and two light chains (L chains) are bound together. The light chain and the heavy chain are bound together by disulfide bonds (SS bonds) to form a heterodimer, and two of these heterodimers are bound together to form a Y-shaped heterotetramer. The heavy chain is composed of a heavy chain variable region VH, heavy chain constant regions CH1, CH2, CH3, and a hinge region located between CH1 and CH2, and the light chain is composed of a light chain variable region VL and a light chain constant region CL. The variable regions include a complementarity-determining region (CDR) and a framework region (FR). The light chain and heavy chain variable regions each have three CDRs (heavy chain CDR1 to 3 and light chain CDR1 to 3) and four FRs (heavy chain FR1 to 4 and light chain FR1 to 4). Methods for identifying CDRs are known, and can be found, for example, in the IMGT / V-QUEST Search page (http: / / www.imgt.org / IMGT_vquest / input), Brochet, X. et al., Nucl. Acids Res. 36, W503-508 (2008) (the entire contents of which are incorporated herein by reference), etc. References: Giudicelli, V., Brochet, X., Lefranc, M.-P., Cold Spring Harb Protoc. 2011 Jun 1;2011(6). pii: pdb.prot5633. doi: 10.1101 / pdb.prot5633. PMID: 21632778), the entire contents of which are incorporated herein by reference). Any other means known in the art that achieves similar results can also be used (Kabat et al., Sequence of Proteins of Immunological Interest (1987), National Institute of Health, Bethesda, Md.; Chothia et al., Nature (1989) 342: 877, the entire contents of which are incorporated herein by reference).

[0016] The antibody or antigen-binding fragment thereof that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention is a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; c) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively; d) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 19, 20, and 21, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23, and 24, respectively; or e) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 28, 29, and 30, respectively; Includes.

[0017] In one embodiment of the invention, an antibody or antigen-binding fragment thereof that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences set forth in a) SEQ ID NOs: 31 and 32, b) SEQ ID NOs: 33 and 34, c) SEQ ID NOs: 35 and 36, d) SEQ ID NOs: 37 and 38, or e) SEQ ID NOs: 39 and 40, respectively.

[0018] The antibodies that bind to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention are based on the five clones #87, #92, #102, #103, and #G46 obtained in the Examples, which have 1C10 binding inhibitory activity. In a binding inhibition test targeting the V3 peptide, these five clones showed no cross-reactivity to the five anti-HIV-1 V3 antibodies KD-247, 5G2, 1D9, 717G2, and 19F8 other than 1C10(0.5γ), and thus had very high specificity for the anti-HIV-1 V3 antibody 1C10(0.5γ).

[0019] Clone #87 comprises a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively. Clone #92 comprises b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively. Clone #102 comprises c) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively. Clone #103 contains d) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 19, 20, and 21, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23, and 24, respectively. Clone #G46 contains e) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 28, 29, and 30, respectively.

[0020] The antibody or antigen-binding fragment thereof of the present invention that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) comprises a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively, and the heavy chain variable region and the light chain variable region each comprise an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequences set forth in SEQ ID NOs: 31 and 32. The antibody or antigen-binding fragment thereof comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 31 or 32 may have amino acid substitutions, deletions, and / or insertions in the framework regions relative to the amino acid sequence set forth in SEQ ID NO: 31 or 32.

[0021] The antibody or antigen-binding fragment thereof of the present invention that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) comprises: b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively; and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; and the heavy chain variable region and the light chain variable region each comprise an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequences set forth in b) SEQ ID NOs: 33 and 34. The antibody or antigen-binding fragment thereof comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 33 or 34 may have amino acid substitutions, deletions, and / or insertions in the framework regions relative to the amino acid sequence set forth in SEQ ID NO: 33 or 34.

[0022] The antibody or antigen-binding fragment thereof of the present invention that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) comprises c) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively, and the heavy chain variable region and the light chain variable region can comprise an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in c) SEQ ID NOs: 35 and 36, respectively. The antibody or antigen-binding fragment thereof comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 35 or 36 can have amino acid substitutions, deletions, and / or insertions in the framework regions with respect to the amino acid sequence set forth in SEQ ID NO: 35 or 36.

[0023] The antibody or antigen-binding fragment thereof of the present invention that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) comprises d) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 19, 20, and 21, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23, and 24, respectively, and the heavy chain variable region and the light chain variable region can comprise an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to d) the amino acid sequence set forth in SEQ ID NOs: 37 and 38, respectively. The antibody or antigen-binding fragment thereof comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 37 or 38 can have amino acid substitutions, deletions, and / or insertions in the framework regions with respect to the amino acid sequence set forth in SEQ ID NO: 37 or 38.

[0024] The antibody or antigen-binding fragment thereof of the present invention that binds to anti-HIV-1 V3 antibody 1C10 comprises e) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 28, 29, and 30, respectively, wherein the heavy chain variable region and the light chain variable region can comprise an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to e) the amino acid sequence set forth in SEQ ID NOs: 39 and 40, respectively. The antibody or antigen-binding fragment thereof comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 39 or 40 can have amino acid substitutions, deletions, and / or insertions in the framework regions relative to the amino acid sequence set forth in SEQ ID NO: 39 or 40.

[0025] Whether any given heavy and light chain variable regions are at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequences of the heavy and light chain variable regions of the present invention can be determined using known sequence comparison algorithms or by manual alignment to obtain the maximum match between the compared sequences within a window or designated region of comparison. For example, the percent identity between sequences can be determined using an algorithm based on the CLUSTALW computer program (Thompson Nucl. Acids Res. 2 (1994), 4673-4680) or FASTDB (Brutlag Comp. App. Biosci. 6 (1990), 237-245). BLAST (Basic Local Alignment Search Tool) and BLAST 2.0 algorithms (Altschul, 1997, Nucl. Acids Res. 25:3389-3402; Altschul, 1993 J. Mol. Evol. 36:290-300; Altschul, 1990, J. Mol. Biol. 215:403-410) can also be used.

[0026] The antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention may be an isolated antibody. The antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention is preferably a monoclonal antibody. The antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention may be a full-length IgG antibody.

[0027] The antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention may comprise a mouse constant region or a human constant region. In one embodiment of the present invention, the antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention is a chimeric antibody comprising a mouse variable region and a human constant region. The chimeric antibody also includes an antigen-binding fragment thereof.

[0028] As used herein, the antigen-binding fragment refers to a fragment of an antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ), specifically, a Fab fragment consisting of VL, VH, CL and CH1 domains; an F(ab') fragment in which two Fabs are linked by a disulfide bond at the hinge domain; 2 Examples of such fragments include, but are not limited to, an Fv fragment consisting of VL and VH; an scFv fragment, which is a single-chain antibody in which VL and VH are linked by an artificial polypeptide linker; and the like.

[0029] An antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention is preferably an anti-idiotype antibody. In the present specification, an anti-idiotype antibody refers to an antibody that binds to the antigen recognition region of an antibody molecule. The anti-idiotype antibody also includes an antigen-binding fragment thereof. An antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention or an antigen-binding fragment thereof can recognize the antigen recognition region of the anti-HIV-1 V3 antibody 1C10(0.5γ). In the following specification, an antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention may be referred to as an anti-1C10 idiotype antibody.

[0030] (epitope) The antibody binding site of the anti-1C10 idiotype antibody of the present invention on the antigen (anti-HIV-1 V3 antibody 1C10(0.5γ)) can be analyzed by epitope mapping using known techniques or by creating mutants of 1C10(0.5γ). Specifically, for example, as in the Examples described below, 1C10(0.5γ) mutants are prepared by arranging each of the regions FR1, CDR1, FR2, CDR2, and FR3 of 1C10(0.5γ) to immunoglobulin germline gene sequences, and the binding activity to each 1C10(0.5γ) mutant is analyzed. Since the anti-HIV-1 V3 antibody 1C10(0.5γ) has a three-dimensional conformation, it may be a discontinuous epitope dependent on the conformation, or it may be a linear epitope composed of a simple linear amino acid sequence.

[0031] From the results of the Examples described below, it was believed that the anti-1C10 idiotype antibody clones #87, #102 and #103 recognize an antigen-binding site including CDR2 of 1C10(0.5γ), clone #92 recognizes an antigen-binding site including FR3 and CDR3 of 1C10(0.5γ), and clone #G46 recognizes an antigen-binding site including CDR1 of 1C10(0.5γ).

[0032] (Affinity) In certain embodiments, the anti-1C10 idiotype antibodies of the invention have a concentration of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.5 nM, ≦0.1 nM, or ≦0.05 nM (e.g., 10 -8 M or less, e.g. 10 -8 M~10 -13 M, for example 10 -9 M~10 -12 M) affinity (binding affinity; K D )

[0033] K Dcan be measured using a surface plasmon resonance assay as in the Examples below. For example, using Biacore (registered trademark) T200, biotinylated 1C10 can be immobilized on a Series S Sensor Chip SA (GE Healthcare), diluted anti-idiotype antibodies can be poured, and the binding and dissociation can be measured. The buffer used is HBS-EP buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05% Surfactant P 20, pH 7.4), and analysis can be performed using the Kinetics / Affinity program of the Biacore (registered trademark) T200 Evaluation Software.

[0034] (Method of producing anti-1C10 idiotype antibody) The method for producing the anti-1C10 idiotype antibody according to the present invention is not limited, but for example, it can be obtained by isolating B cells from a non-human mammal immunized with the anti-HIV-1 V3 antibody 1C10 (0.5γ) or a fragment thereof, amplifying an antibody gene from one B cell, expressing the antibody in animal cells such as CHO cells or HEK293 cells, evaluating the antibody performance, synthesizing an IgG antibody gene from the obtained genetic information, and expressing the antibody in HEK293 cells or the like. The antibody can also be obtained by fusing the antibody-producing cells isolated from the immunized non-human mammal with myeloma cells or the like to prepare a hybridoma, and purifying the antibody produced by the hybridoma.

[0035] When the anti-1C10 idiotype antibody of the present invention is produced by a genetic recombination method, for example, an appropriate host may be transformed with an expression vector containing the nucleic acid of the present invention, and the transformant may be cultured under appropriate conditions to express the antibody, which may then be isolated and purified according to a known method. Examples of the isolation and purification method include affinity columns using protein A or the like, other chromatography columns, filters, ultrafiltration, salting out, and dialysis, and these may be combined as appropriate.

[0036] The antigen-binding fragment of the present invention may be produced by the above-mentioned genetic recombination method using DNA encoding the fragment, or the full-length antibody may be obtained and then fragmented by treating it with an enzyme such as papain or pepsin.

[0037] (nucleic acid) The present invention also encompasses nucleic acids encoding the anti-1C10 idiotype antibody or antigen-binding fragment thereof according to the present invention. The nucleic acid may be a natural nucleic acid or an artificial nucleic acid, for example, but is not limited to, DNA, RNA, or a chimera of DNA and RNA. The base sequence of the nucleic acid encoding the anti-1C10 idiotype antibody or antigen-binding fragment thereof can be determined by a person skilled in the art according to a known method, and can be prepared by a known method.

[0038] Examples of the nucleic acid encoding the anti-1C10 idiotype antibody or an antigen-binding fragment thereof according to the present invention include: DNA encoding a heavy chain comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; DNA encoding a light chain comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; DNA encoding a heavy chain comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively; DNA encoding a light chain comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; DNA encoding a heavy chain comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively; DNA encoding a light chain comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively; DNA encoding a heavy chain comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 19, 20, and 21, respectively; DNA encoding a light chain comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23, and 24, respectively; DNA encoding a heavy chain comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27, respectively; and Examples of such DNA include, but are not limited to, DNA encoding a light chain comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 28, 29, and 30, respectively.

[0039] (Expression Vector) The present invention also encompasses an expression vector comprising a nucleic acid encoding the anti-1C10 idiotype antibody of the present invention or an antigen-binding fragment thereof. The expression vector can be appropriately selected according to the host cell to be used. The nucleic acid encoding the anti-1C10 idiotype antibody of the present invention or an antigen-binding fragment thereof can be inserted into these expression vectors by known methods (such as a method using a restriction enzyme). The expression vector according to the present invention can further comprise a promoter that regulates the expression of the antibody gene, a replication origin, a selection marker gene, and the like. The promoter and replication origin can be appropriately selected depending on the type of the host cell and the vector.

[0040] (Transformant) The present invention includes a transformant containing the vector of the present invention. The transformant can be obtained by transfecting the vector of the present invention into an appropriate host cell or host organism. As the host cell, for example, eukaryotic cells such as mammalian cells (CHO cells, COS cells, myeloma cells, HeLa cells, Vero cells, HEK293, etc.), insect cells, plant cells, fungal cells (Saccharomyces, Aspergillus, etc.), and prokaryotic cells such as Escherichia coli (E. coli) and Bacillus subtilis can be used. As the host organism, for example, silkworms can be used.

[0041] The present invention can provide a pharmaceutical composition comprising any of the above-mentioned anti-1C10 idiotype antibodies or antigen-binding fragments thereof. The pharmaceutical composition of the present invention can contain a pharma- ceutical acceptable carrier or excipient. The pharmaceutical composition of the present invention can be used for the diagnosis and treatment of HIV-1 infection.

[0042] (Detection agent for anti-HIV-1 V3 antibody 1C10 (0.5γ)) The present invention can provide a detection agent for anti-HIV-1 V3 antibody 1C10(0.5γ), comprising any of the above-mentioned antibodies or antigen-binding fragments thereof that bind to the anti-HIV-1 V3 antibody 1C10(0.5γ). The detection agent of the present invention can further comprise a label. Labels include, but are not limited to, fluorescent labels, enzyme labels, biotin, magnetic beads, agarose beads, magnetic agarose beads, gold colloids, and rare earth fluorescent complexes. Labels can be used alone or in combination.

[0043] Examples of labels include, but are not limited to, low molecular weight fluorescent dyes such as fluorescein isothiocyanate (FITC), Alexa Fluor (registered trademark) dyes, and Cy dyes; fluorescent proteins such as phycoerythrin (PE) and allophycocyanin (APC); enzyme labels such as horseradish peroxidase (HRP) (chromogenic substrates are TMB, OPD, ABTS, etc.) and alkaline phosphatase (AP) (chromogenic substrates are BCIP / NBT, pPNPP, etc.); biotin / avidin; magnetic beads used in immunoprecipitation, agarose beads, magnetic agarose bead labels, gold colloid labels used in immunoelectron microscopy, and rare earth fluorescent complex labels such as ruthenium complexes (sulfo-tags). In addition, radioisotopes 32 P, 14 C. 125 I, 3 H and 131 I can also be used for labeling. In one embodiment, the detection agent comprises a labeled anti-1C10 idiotype antibody or an antigen-binding fragment thereof.

[0044] (Detection method for anti-HIV-1 V3 antibody 1C10 (0.5γ)) The present invention provides a method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample, comprising the steps of: A method can be provided, comprising the steps of contacting the sample with either an antibody or an antigen-binding fragment thereof that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ), and detecting the anti-HIV-1 V3 antibody 1C10(0.5γ) bound to the antibody or antigen-binding fragment thereof that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ).

[0045] In the above detection method, the anti-HIV-1 V3 antibody 1C10(0.5γ) can be detected in a sample when it is present using the anti-1C10 idiotype antibody of the present invention or an antigen-binding fragment thereof. This detection can be performed by any conventional immunological measurement method. The detection method of the present invention can be performed in vitro or ex vivo.

[0046] The sample may be blood or a fraction or a processed product thereof (e.g., plasma or serum), with serum being preferred. In some cases of human HIV-1 infection, anti-HIV-1 V3 antibodies other than 1C10(0.5γ) are induced, but the antibody or antigen-binding fragment thereof that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) of the present invention can specifically bind to 1C10(0.5γ), and therefore can be used to detect 1C10(0.5γ) in a human-derived sample.

[0047] In the above detection methods, the anti-1C10 idiotype antibody or antigen-binding fragment thereof can be labeled with the labels described above.

[0048] In the above detection method, the anti-1C10 idiotype antibody or its antigen-binding fragment may be used in a soluble state not bound to anything, or may be bound to a solid phase. Examples of the "solid phase" include plates (e.g., microwell plates), tubes, beads (e.g., plastic beads, magnetic beads), chromatographic supports (e.g., water-absorbent substrates such as nitrocellulose membranes, Sepharose), membranes (e.g., nitrocellulose membranes, PVDF membranes), gels (e.g., polyacrylamide gels), and metal membranes (e.g., gold membranes).

[0049] In one embodiment of the present invention, the detection of the anti-HIV-1 V3 antibody 1C10(0.5γ) can be carried out by detecting a labeled anti-1C10 idiotype antibody or an antigen-binding fragment thereof by a direct method, for example, by immobilizing the anti-HIV-1 V3 antibody 1C10(0.5γ) on a microplate or the like, reacting with the anti-1C10 idiotype antibody or an antigen-binding fragment thereof labeled with an enzyme or the like, washing, and then detecting the enzyme activity remaining on the microplate.

[0050] In another embodiment of the present invention, the detection of the anti-HIV-1 V3 antibody 1C10(0.5γ) can be performed by a sandwich assay (sandwich immunoassay). A sandwich assay is a method that uses two antibodies that bind to different epitopes on an antigen. A capture antibody with high binding specificity for the antigen of interest is bound to a solid phase or solid surface. A sample containing the antigen is then added, followed by the addition of a detection antibody. The detection antibody binds to a different epitope than the capture antibody.

[0051] In the sandwich assay of the present invention, any one of the anti-1C10 idiotype antibodies or antigen-binding fragments thereof may be used in combination with an anti-human IgG antibody, or any two of the anti-1C10 idiotype antibodies or antigen-binding fragments thereof may be used. A specific detection method when one type of anti-1C10 idiotype antibody or antigen-binding fragment thereof is used is, for example, to immobilize any one of the antigen-binding fragments of the anti-1C10 idiotype antibody on a plate or the like, add a sample, and detect the bound 1C10 with a detectably labeled anti-human IgG antibody.

[0052] The detection method can be any known method, for example, enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence assay (ECL), surface plasmon resonance (SPR), etc. can be used, and ELISA or electrochemiluminescence assay is preferably used. In ELISA, for example, anti-1C10 idiotype antibody is immobilized on a microplate, reacted with anti-HIV-1 V3 antibody 1C10 (0.5γ), then reacted with another enzyme-labeled anti-1C10 idiotype antibody, and after washing, the enzyme activity remaining on the microplate can be detected. ECL can also respond to a sandwich assay like ELISA, and anti-1C10 idiotype antibody is immobilized on a microplate, reacted with anti-HIV-1 V3 antibody 1C10 (0.5γ), then reacted with another anti-1C10 idiotype antibody labeled with a ruthenium complex, and electrochemical stimulation is generated on the electrode of the microplate, causing the ruthenium complex to emit light, which can be detected.

[0053] The capture antibody of the sandwich assay may be any of the anti-1C10 idiotype antibodies and their antigen-binding fragments, and the detection antibody of the sandwich assay may be any of the anti-1C10 idiotype antibodies and their antigen-binding fragments. The capture antibody and detection antibody of the sandwich assay may be different types of anti-1C10 idiotype antibodies or the same type of anti-1C10 idiotype antibodies. The sandwich assay is a method in which two antibodies that bind to different epitopes on an antigen are used as the capture antibody and the detection antibody, respectively. However, the anti-1C10 idiotype antibody of the present invention targets the bivalent anti-HIV-1 V3 antibody 1C10 (0.5γ) and has the same type of epitope at two locations, so that the same type of anti-1C10 idiotype antibody can be used as the capture antibody and the detection antibody. On the other hand, for the purpose of increasing the specificity of detection, it is preferable to use different types of anti-1C10 idiotype antibodies as the capture antibody and the detection antibody of the sandwich assay of the present invention. This is because the capture antibody and detection antibody recognize different types of epitopes of the anti-HIV-1 V3 antibody 1C10 (0.5γ), thereby increasing the specificity of detection.

[0054] In the detection method of the present invention using a sandwich assay, the capture antibody a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; c) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively; d) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 19, 20, and 21, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23, and 24, respectively; or e) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 28, 29, and 30, respectively; and wherein the antibody or antigen-binding fragment thereof comprises The above detection antibody a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; c) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively; d) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 19, 20, and 21, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23, and 24, respectively; or e) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 28, 29, and 30, respectively; The antibody or antigen-binding fragment thereof may be an antibody comprising:

[0055] In the detection method of the present invention using a sandwich assay, The above capture antibody a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; or b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; and wherein the antibody or antigen-binding fragment thereof comprises The above detection antibody a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; or b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; The antibody or antigen-binding fragment thereof may be an antibody comprising:

[0056] In a particular embodiment of the invention, the capture antibody is a) an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; The above detection antibody b) It may be an antibody or an antigen-binding fragment thereof comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively.

[0057] In a particular embodiment of the invention, the capture antibody is b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; and wherein the antibody or antigen-binding fragment thereof comprises The above detection antibody a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; The antibody or antigen-binding fragment thereof may be an antibody comprising:

[0058] In the detection method of the present invention using a sandwich assay, the capture antibody may be the full-length IgG antibody of the anti-1C10 idiotype antibody or an antigen-binding fragment thereof, and similarly, the detection antibody may be the full-length IgG antibody or an antigen-binding fragment thereof. Examples of the antigen-binding fragment include the above-mentioned Fab fragment and F(ab') 2 Examples of the antibody may include, but are not limited to, a fragment, an Fv fragment, or an scFv fragment. The selection of the form of the capture antibody and the detection antibody, either a full-length IgG antibody or an antigen-binding fragment, can be appropriately determined depending on the type of sandwich assay (ELISA, ECL, etc.) and the type of label. In one embodiment, the capture antibody may be an antigen-binding fragment, and the detection antibody may be a full-length IgG antibody. In another embodiment, both the capture antibody and the detection antibody may be antigen-binding fragments. In yet another embodiment, the capture antibody may be a full-length IgG antibody, and the detection antibody may be an antigen-binding fragment. In yet another embodiment, both the capture antibody and the detection antibody may be full-length IgG antibodies.

[0059] In a particular embodiment of the invention, the capture antibody is b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; an antigen-binding fragment of an antibody comprising The above detection antibody a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; The antibody can be an antibody comprising: In the Examples described below, it has been demonstrated that the combination of coating with Fab#92 as a capture antibody and detection with IgG#87 as a detection antibody provides the highest detection sensitivity for 1C10 and the highest signal.

[0060] The anti-idiotype antibodies of the present invention are divided into three groups based on the difference in epitope: 1) #87, #102, #103; 2) #92; and 3) #G46. It is preferable that the capture antibody and the detection antibody in the sandwich assay are selected from different groups. Examples of combinations of capture antibody and detection antibody in the sandwich assay include the combination of #87 and #92, the combination of #87 and #G46, the combination of #102 and #92, the combination of #102 and #G46, the combination of #103 and #92, the combination of #103 and #G46, and the combination of #92 and #G46. Any one of the combinations can be used as the capture antibody and the other as the detection antibody.

[0061] According to the present invention, 1C10(0.5γ) can be detected even when the concentration of 1C10(0.5γ) in a sample is 0.1 μg / mL or less, 0.05 μg / mL or less, or 0.01 μg / mL or less. In the Examples described below, when coated with Fab#92, 1C10 was detected even at 0.01 μg / mL or less. The detection sensitivity of conventional ELISA using V3 peptide is about 10 μg / mL, but according to the present invention, detection with higher sensitivity than conventional methods is possible.

[0062] According to the present invention, there is provided a method for determining the concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample, comprising the steps of: A method can be provided which comprises the step of determining the concentration of anti-HIV-1 V3 antibody 1C10 in a sample using the above-mentioned method for detecting anti-HIV-1 V3 antibody 1C10 (0.5γ) in a sample.

[0063] Determining the concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample includes measuring the amount of anti-HIV-1 V3 antibody 1C10(0.5γ) bound to an antibody or antigen-binding fragment thereof that binds to anti-HIV-1 V3 antibody 1C10(0.5γ) and calculating the concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in the sample. The concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample can be calculated by performing two-point or three-point measurements for both the sample and the standard substance for the standard curve, creating a standard curve, and reading the concentration of the sample from the absorbance of the sample on this standard curve.

[0064] According to the present invention, there is provided a method for determining or monitoring the effectiveness of treatment with anti-HIV-1 V3 antibody 1C10(0.5γ) in a subject suffering from HIV-1 infection, comprising the steps of: determining the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample from a subject previously administered anti-HIV-1 V3 antibody 1C10(0.5γ) using the method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in the sample; and A method can be provided that includes comparing the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a control sample with the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample from the subject.

[0065] In this specification, the level means an index relating to the amount of abundance quantified, and includes, for example, concentration, amount, or an index that can be used instead of the concentration. Thus, the level may be a measured value such as fluorescence intensity, or a value converted into concentration. In addition, the level may be an absolute value (abundance, amount per unit area, etc.), or may be a relative value compared to a control set as necessary.

[0066] In one embodiment of the invention, a method for providing data for determining or monitoring the effectiveness of treatment with anti-HIV-1 V3 antibody 1C10(0.5γ) in a subject suffering from HIV-1 infection, comprising the steps of determining the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample from a subject previously administered anti-HIV-1 V3 antibody 1C10(0.5γ) using a method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in the sample, and A method can be provided that includes a step of comparing the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a control sample with the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample from a subject, thereby obtaining data for determining or monitoring the effectiveness of treatment with anti-HIV-1 V3 antibody 1C10(0.5γ).

[0067] The sample may be a blood sample, preferably a serum sample.The subject is a mammal, preferably a human.

[0068] The difference between the anti-HIV-1 V3 antibody 1C10(0.5γ) level in the control sample and the anti-HIV-1 V3 antibody 1C10(0.5γ) level in the sample from the subject is an indication of whether the subject responds to treatment with the anti-HIV-1 V3 antibody 1C10(0.5γ). The anti-HIV-1 V3 antibody 1C10(0.5γ) level in the control sample may be a level in a patient known to respond to treatment with the anti-HIV-1 V3 antibody 1C10(0.5γ) (e.g., an HIV patient in which neutralization has been confirmed after administration of the anti-HIV-1 V3 antibody 1C10(0.5γ)), or may be a standardized level between multiple such patients. Alternatively, the anti-HIV-1 V3 antibody 1C10(0.5γ) level in the control sample may be a level in a patient known to be non-responsive to treatment with anti-HIV-1 V3 antibody 1C10(0.5γ) (e.g., an HIV patient in whom neutralization was not observed after administration of anti-HIV-1 V3 antibody 1C10(0.5γ)), or may be a standardized level among multiple such patients.

[0069] A subject having an anti-HIV-1 V3 antibody 1C10(0.5γ) level equal to or higher than the anti-HIV-1 V3 antibody 1C10(0.5γ) level in the responsive control sample can be judged to be highly likely to obtain a therapeutic effect from the anti-HIV-1 V3 antibody 1C10(0.5γ). A subject having an anti-HIV-1 V3 antibody 1C10(0.5γ) level equal to or lower than the anti-HIV-1 V3 antibody 1C10(0.5γ) level in the non-responsive control sample can be judged to be low likely to obtain a therapeutic effect from the anti-HIV-1 V3 antibody 1C10(0.5γ).

[0070] The efficacy of treatment with anti-HIV-1 V3 antibody 1C10(0.5γ) can be monitored, for example, by determining the level of anti-HIV-1 V3 antibody 1C10(0.5γ) at one or more time points after administration of anti-HIV-1 V3 antibody 1C10(0.5γ). Monitoring the level of anti-HIV-1 V3 antibody 1C10(0.5γ) is important to enhance the overall efficacy of treatment with anti-HIV-1 V3 antibody 1C10(0.5γ). For example, in patients who are responsive to anti-HIV-1 V3 antibody 1C10(0.5γ), when the level of anti-HIV-1 V3 antibody 1C10(0.5γ) falls below a certain level, supplementation with administration of anti-HIV-1 V3 antibody 1C10(0.5γ) may enhance the efficacy of treatment.

[0071] In a non-human primate model, it was revealed that the neutralizing effect of the anti-HIV-1 V3 antibody 1C10(0.5γ) correlates with its blood concentration, so that in human clinical trials, it is important to measure the blood concentration of the anti-HIV-1 V3 antibody 1C10(0.5γ) in patients administered with the anti-HIV-1 V3 antibody 1C10(0.5γ). According to the present invention, the blood concentration of the anti-HIV-1 V3 antibody 1C10(0.5γ) can be specifically quantified, which is useful for developing a treatment for HIV-1 infection using the anti-HIV-1 V3 antibody 1C10(0.5γ) as a neutralizing antibody, for determining whether HIV-1-infected patients respond to this neutralizing antibody, or for monitoring the course of treatment. EXAMPLES

[0072] The present invention will be described in more detail based on the following examples, but the present invention is not limited to these examples. In this specification, unless otherwise specified, "%" and the like are based on mass, and numerical ranges are described as including their endpoints.

[0073] Example 1: Isolation of anti-idiotypic antibodies <Method> 1) Immunization of mice with anti-HIV-1 V3 antibody 1C10 (0.5γ) and isolation of anti-idiotypic antibody-producing B cells 200 μg of anti-V3 antibody 1C10 (0.5γ) was administered subcutaneously to 6-week-old BALB / C mice together with the commercially available adjuvant TiterMax® Gold Adjuvant liquid (Sigma-Aldrich, MO, US), and then equal amounts of 1C10 and adjuvant were administered via tail vein injection four times every two weeks for a total of five administrations. Mice were sacrificed 2-3 days after the last 1C10 administration (week 8), and spleens were collected. B cells were separated from lymphocytes obtained from the spleen using MojoSort® (Biolegend, CA, US), stained with antibodies, and analyzed for CD19 by FACS Aria® II. + , 7-AAD - , IgM - , IgG + , 1C10 + The cells were single-cell sorted onto a 96-well plate. Staining with 1C10 was performed using biotinylated 1C10 and allophycocyanin (APC)-labeled streptavidin as a secondary antibody.

[0074] 2) Amplification of immunoglobulin variable regions by RT-PCR The reagents used for RT-PCR are shown in Table 1. The cells that were subjected to the single cell sorting were dissolved in guanidine thiocyanate, and the remaining reagents in Table 1 were added, and reverse transcription was performed at 42°C for 10 minutes, 25°C for 10 minutes, 50°C for 60 minutes, and 94°C for 5 minutes. The primers used were those described in T Tiller et al. J Immunol Methods. 2009 (https: / / doi.org / 10.1016 / j.jim.2009.08.009) (the entire contents of which are incorporated herein by reference).

[0075] [Table 1]

[0076] The variable regions (VH and VL) of the immunoglobulin heavy chain (HC) and light chain (LC) of the synthesized cDNA were amplified by nested PCR. st PCR) and the second PCR (2 nd The reagents used in PCR are shown in Tables 3 and 4. The first PCR was performed by mixing the reagents shown in Table 2, heating at 95°C for 5 minutes, performing 50 cycles of 94°C for 30 seconds, 62°C for 30 seconds, and 72°C for 45 seconds (the annealing temperature was lowered at -0.4°C / cycle until the 25th cycle, and was performed at 52°C from the 26th cycle onwards), and heating at 72°C for 10 minutes. The second PCR was performed by mixing the reagents shown in Table 3, heating at 95°C for 5 minutes, performing 50 cycles of 94°C for 10 seconds, 55°C for 10 seconds (HC 55°C, LC 65°C), and 72°C for 15 seconds (HC: -0.2°C / cycle until the 25th cycle, and 50°C from the 26th cycle onwards; LC: -0.4°C / cycle until the 25th cycle, and 55°C from the 26th cycle onwards), and heating at 72°C for 4 minutes. The primers used were those described in S Rohatgi et al. J Immunol Methods. 2008 (https: / / doi.org / 10.1016 / S0022-1759(00)00337-9) (the entire disclosure of which is incorporated herein by reference).

[0077] [Table 2] [Table 3]

[0078] 3) Construction of IgG expression plasmid and IgG production The immunoglobulin variable regions amplified by RT-PCR were electrophoresed on a 1% agarose gel, and DNA of 400 to 500 bp in length corresponding to VH and VL was extracted using a QIAquick® Gel Extraction Kit (QIAGEN, Hilden Germany). 20 ng of the purified PCR product was mixed with 400 ng of expression vector (HC: pIgGH, LC: pKVA2; Ramirez, K, et al., 2015 (supra)) and Gibson Assembly® Master Mix (New England Biolabs, MA, US), and the PCR product was inserted into the vector by homologous recombination. The above expression vectors are for expressing human IgG. One Shot TOP10 Chemically Competent E. coli (Invitrogen, NY, US) was transformed with the recombinant DNA, and the HC and LC expression plasmids were cloned. GenElute TM The cloned plasmids were purified using a Plasmid Miniprep Kit (Sigma-Aldrich, MO, US), and 500 ng each of the HC and LC plasmids were mixed with 1.5 μL of FectPRO (PolyPlus, Illkirch, France) and transfected into HEK293T cells. The 1C10 binding inhibitory activity of the supernatant obtained 48 hours later was measured by ELISA as described below, and clones with 1C10 binding inhibitory activity were used as anti-1C10 idiotype antibodies for subsequent analysis.

[0079] 4) Purification of anti-1C10 idiotype antibody Five antibodies (#87, #92, #102, #103, #G46) with 1C10 binding inhibitory activity were transfected into HEK293A cells, and colony-forming cells were selected with 0.625 mg / mL G418 sulfate (MerkMillipore, MA, US) and 0.15 mg / mL hygromycin (Nacalai tesqu, Kyoto, Japan). A cell line with high IgG production was cultured for a long period of time, and the supernatant was collected and analyzed by HiTrap. TM IgG was purified using a Protein A HP column (GE Healthcare, IL, US). The eluate was dialyzed using a Spectra / Por® 1 Dialysis Sack, 6-8KD (Isher Scientific, Goteborg, Sweden), and the buffer was replaced with PBS.

[0080] 5) Measurement of 1C10 binding inhibition activity by ELISA Nunc MaxiSorp coated with 0.2 μg of NNT20 (NNTRKSIHIGPGRAFYTTGE: SEQ ID NO: 43), a V3 peptide of HIV-1 JR-FL strain, per well TMFlat-bottom plates (Invitrogen, NY, US) were washed once with ELISA washing buffer (Na2HPO4 70.4 mM, KH2PO4 14.6 mM, NaCl 1.3 M, KCl 26.8 mM, NaN3 30.7 mM), then blocked with FACS buffer (2% BSA, 0.1% azide, PBS pH 7.2) at 37℃ for 30 minutes. After washing twice, 50 μL of anti-1C10 idiotype antibody samples such as culture supernatant or purified IgG (#87, #92, #102, #103, or #G46) were added to each well and incubated at 37℃ for 30 minutes. Then, 0.025 μg of biotinylated 1C10 was added and incubated at 37° C. for 60 minutes, after which 0.02 μg (in 100 μL of ELISA buffer) of Streptavidin (SA)-Peroxidase (Sigma-Aldrich, MO, US) was added and left at room temperature for 60 minutes, and the OD value was measured using an ELISA Reader after color development with ABTS, an HRP substrate. The 1C10 binding inhibitory activity of the five anti-1C10 idiotype antibody samples obtained in this example was shown by a relative decrease in OD value compared to wells that did not contain the anti-1C10 idiotype antibody sample.

[0081] Five anti-HIV-1 V3 antibodies other than 1C10, namely, KD-247, 5G2, 1D9, 717G2, and 19F8, were also biotinylated and assayed for their binding inhibitory activity by anti-1C10 idiotype antibody samples (#87, #92, #102, #103, or #G46).

[0082] 6) Biotinylation of antibodies For antibody biotinylation, the purified antibody was biotinylated using EZ-Link NHS-LC-LC-Biotin (ThermoFisher, MA, US) according to the attached protocol. That is, 1 mg of EZ-Link NHS-LC-LC-Biotin was dissolved in 175 μL of DMSO, and 1.33 μL was added to 100 μL of antibody adjusted to 1 mg / mL with PBS, and reacted at room temperature for 30 minutes. Then, 400 μL of PBS was added to an Amicon Ultra 0.5 mL centrifugal filter 50K (Merk Millipore, Darmstadt, Germany), and centrifuged at 13,000 g for 4 minutes, discarding the waste liquid and washing. The same procedure was repeated three times in total to remove excess biotin particles, and the sample was collected in a 1.5 mL tube.

[0083] <Result> Mice were immunized with the anti-HIV-1 V3 antibody 1C10, and five anti-1C10 idiotypic antibody clones (#87, #92, #102, #103, and #G46) were isolated by single cell sorting and antibody gene cloning (Figs. 1 and 2). These anti-1C10 idiotypic antibodies showed no cross-reactivity with the other five anti-HIV-1 V3 antibodies, KD-247, 5G2, 1D9, 717G2, and 19F8, and were highly specific to 1C10 (Fig. 3B).

[0084] Example 2: Epitope analysis of anti-idiotype antibodies <Method> 1) Generation of 1C10 germline reverted mutants Using the 1C10 HC expression vector as a template, the regions of VH other than CDR3 were amplified by overlap PCR using the primers shown in Table 4, and 1C10 mutants were produced in which the FR1, CDR1, FR2, CDR2, and FR3 regions of 1C10 were made to have immunoglobulin germline gene sequences. The positions of the overlap PCR primers are shown in Figure 4A. [Table 4] PCR was performed by mixing 10 μL of 2X SapphireAmp Fast PCR Master Mix (TAKARA, Shiga, Japan), 7.5 μL of nuclease-free water, 0.4 μL of 10 μM F primer, 0.4 μL of 10 μM R primer, and 1 μL of template, heating at 95 ° C for 5 minutes, followed by 30 cycles of 94 ° C for 5 seconds, 54 ° C for 5 seconds, and 72 ° C for 5 seconds, 72 ° C for 4 minutes, and then at 4 ° C. The PCR product was gel electrophoresed, extracted with QIAquick Gel Extraction Kit (QIAGEN, Hilden Germany), and incorporated into pIgGH. As a result of PCR-mutagenesis, we generated FR1-reverted mutants (FR1-R), CDR1-reverted mutants (CDR1-R), FR2-reverted mutants (FR2-R), CDR2-reverted mutants (CDR2-R), and FR3-reverted mutants (FR3-R), as well as the inferred germline 1C10 (IG) in which all of these regions were substituted for the immunoglobulin germline gene sequence (Fig. 4B). These 1C10 HC mutant expression vectors were co-transfected into HEK293 cells with the LC expression vector, and the 1C10 mutants were collected from the supernatant.

[0085] 2) Analysis of binding activity of anti-idiotypic antibodies to 1C10 mutants by ELISA Anti-human IgG (γ-chain specific) antibody (Sigma-Aldrich, MO, US) was diluted 1:10,000 with bicarbonate buffer (64 mM Na2CO3, 136 mMNaHCO3, pH 9.6) in a Nunc MaxiSorp flat-bottom plate, and 100 μL / well was added and left overnight at 4°C. After washing once with ELISA washing buffer, 200 μL of FACS buffer was added and left at 37°C for 30 minutes. After washing twice, 1C10 mutant and 1C10 were added and reacted at 37°C for 1 hour. After washing once with ELISA washing buffer, 10 μg of polyglobin-N (PGN) was added at 100 μL / well and blocked at 37°C for 30 minutes. After washing twice, biotinylated anti-Id antibody was added and reacted at 37°C for 1 hour. After washing three times, SA-Peroxidase was added and reacted at room temperature for 1 hour. After washing three times, 100 μL of ABTS solution was added and the absorbance at OD405 nm was measured using a luminometer. The measured OD value was calculated as a relative value to 1C10 and compared.

[0086] <Result> We created 1C10 mutants by changing the amino acid sequence of the VH region of 1C10 to the sequence of VH3-30, which is the immunoglobulin germline gene of 1C10, for each of the regions FR1, CDR1, FR2, CDR2, and FR3 (Fig. 4), and measured the binding of anti-idiotype antibodies to the 1C10 mutants by ELISA (Fig. 5). None of the five anti-idiotype antibodies were able to bind to the IG of the 1C10 mutant, in which all regions from FR1 to FR3 were changed to the immunoglobulin germline gene sequence.

[0087] In Figure 5, anti-idiotype antibodies #87, #102, and #103 showed significantly reduced binding activity to mutant CDR2-R. In addition, #92 showed reduced binding activity to FR3-R, and #G46 showed reduced binding activity to CDR1-R. The regions with significantly reduced binding in Figure 5 are considered to be involved in binding, and these regions and the region containing CDR3, etc. are considered to be the epitope. As for #92, the antigen-binding site of 1C10, which is greatly affected by the mutation of FR3, is CDR3, so it is considered that CDR3 is largely involved in the epitope of #92. From this, it was considered that the anti-idiotype antibodies of the five clones could be divided into three groups based on the difference in epitopes.

[0088] Example 3: Preparation of a 1C10 detection system using anti-idiotype antibodies <Method> 1) Preparation and purification of Fab The PCR product of the amplified VH region was cloned into a Fab heavy chain expression vector in the same manner as for the preparation of IgG. The Fab heavy chain expression vector and the light chain expression vector were transfected into HEK293A cells, and Fab-producing cell lines were selected with G418 sulfate and hygromycin and cultured for a long period of time. Fab was purified from the culture supernatant using His60 Ni Superflow Resin (TAKARA, Shiga, Japan), and the eluate was replaced with PBS by dialysis.

[0089] 2) Sandwich ELISA 1 μg of anti-idiotypic antibody Fab (in 100 μL of PBS) was added to Nunc MaxiSorp TMThe plates were placed in a flat-bottom and left overnight at 4°C. The plates were washed once with ELISA washing buffer using a CappWash ELISA Plate Washer, and 200μL of FACS buffer was added and left at 37°C for 30 minutes. The plates were then washed twice using the above method, and 125μL of 1C10 and Polyglobin-N (PGN) were added at 0.25μg each to two columns, and samples were added to the top wells of the six rows, excluding one well each on the outer periphery of the plate from the fifth row onwards, and 100μL of ELISA buffer was added to the second to sixth rows. Using a multipipettor, 25μL of the sample was transferred from the top row to the second row and mixed by pipetting, and the same process was repeated from the second row to the third row, diluting the sample 5-fold to 3125-fold, and 25μL of the liquid was aspirated from the sixth well and discarded into the empty wells at the bottom row (Figure 6). After 1 hour of reaction at 37℃, the wells were washed twice with ELISA washing buffer, and 100μL of 0.2μg of biotinylated anti-idiotype antibody IgG was added to each well and reacted at 37℃ for 1 hour. After washing three times, 100μL of SA-Peroxidase diluted 5,000 times with ELISA buffer was added to each well and reacted at room temperature for 1 hour. After washing three times, 100μL of ABTS solution was added, and the absorbance at OD405nm was measured using an ELISA Reader. Figure 7 shows a schematic diagram of sandwich ELISA.

[0090] <Result> When 1C10 was detected by sandwich ELISA using anti-idiotype antibody Fab and IgG, the strongest signal was observed when anti-idiotype antibody Fab#87 or Fab#103 was coated and detected with biotinylated IgG#87 (Fig. 8). When the detection sensitivity of 1C10 was compared between the coating Fabs in the detection system using biotinylated IgG#87, which had the highest signal intensity, strong signals were detected at high concentrations of 1C10 when coated with Fab#103 and Fab#87, but were not detectable at 0.01 μg / mL (Fig. 9). On the other hand, when coated with Fab#92, 1C10 was detected even at concentrations of 0.01 μg / mL or less.

[0091] To examine in more detail the combination of anti-idiotypic antibodies #87 and #92, which had the highest 1C10 detection sensitivity, sandwich ELISA was performed using three combinations: Fab#92 and IgG#87, Fab#87 and IgG#87, and Fab#87 and IgG#92. The combination of coating with Fab#92 and detection with IgG#87 showed the highest 1C10 detection sensitivity and strongest signal (Figure 10).

[0092] Example 4: Measurement of binding activity of anti-idiotype antibodies <Method> Binding activity measurement using surface plasmon resonance (SPR) method To evaluate the binding activity of the anti-idiotype antibody to 1C10, the affinity (binding affinity; K D ) was measured. Biotinylated 1C10 was immobilized on a Series S Sensor Chip SA (GE Healthcare), and diluted anti-idiotypic antibodies were poured into the solution to measure the binding and dissociation. HBS-EP buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05% Surfactant P 20, pH 7.4) was used as the buffer, and analysis was performed using the Kinetics / Affinity program of the Biacore (registered trademark) T200 Evaluation Software.

[0093] <Result> 1C10 was immobilized on a sensor chip, and binding of the anti-idiotype antibody was analyzed using Biacore® T200. The results are shown in Table 5 and Figure 11. [Table 5] The K of the measured anti-idiotype antibody D The values ​​were very low, ranging from 0.0343 nM to 0.327 nM, indicating that the compound has a very strong affinity for 1C10. In particular, #87 had a very low K DThis strong affinity was thought to be the reason why #87 had the highest sensitivity in detecting 1C10 by ELISA. [Sequence List Free Text]

[0094] SEQ ID NOs: 1 to 40: Amino acid sequences of anti-idiotype antibodies #87, #92, #102, #103, or #G46 SEQ ID NOs: 41-42: Amino acid sequences of the heavy and light chains of anti-HIV-1 V3 antibody 1C10 (0.5γ) SEQ ID NO: 43: Amino acid sequence of V3 peptide NNT20 of HIV-1 JR-FL strain SEQ ID NOs: 44 to 56: Primer sequences

Claims

1. An antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) (anti-1C10(0.5γ) antibody) or an antigen-binding fragment thereof, the heavy chain variable region of the anti-1C10(0.5γ) antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:31; and the light chain variable region of the anti-1C10(0.5γ) antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 32; with the proviso that the heavy chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; and the light chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively; An anti-1C10(0.5γ) antibody or an antigen-binding fragment thereof, wherein the anti-HIV-1 V3 antibody 1C10(0.5γ) comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 41 and 42, respectively.

2. An antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) (anti-1C10(0.5γ) antibody) or an antigen-binding fragment thereof, the heavy chain variable region of the anti-1C10(0.5γ) antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:33; and the light chain variable region of the anti-1C10(0.5γ) antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 34; with the proviso that the heavy chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of SEQ ID NOs: 7, 8, and 9, respectively; and the light chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of SEQ ID NOs: 10, 11, and 12, respectively; An anti-1C10(0.5γ) antibody or an antigen-binding fragment thereof, wherein the anti-HIV-1 V3 antibody 1C10(0.5γ) comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 41 and 42, respectively.

3. An antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) (anti-1C10(0.5γ) antibody) or an antigen-binding fragment thereof, the heavy chain variable region of the anti-1C10(0.5γ) antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:35; and the light chain variable region of the anti-1C10(0.5γ) antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 36; and wherein the heavy chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively; and the light chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively; An anti-1C10(0.5γ) antibody or an antigen-binding fragment thereof, wherein the anti-HIV-1 V3 antibody 1C10(0.5γ) comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 41 and 42, respectively.

4. An antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) (anti-1C10(0.5γ) antibody) or an antigen-binding fragment thereof, the heavy chain variable region of the anti-1C10(0.5γ) antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:37; and the light chain variable region of the anti-1C10(0.5γ) antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:38; and wherein the heavy chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of SEQ ID NOs: 19, 20, and 21, respectively; and the light chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of SEQ ID NOs: 22, 23, and 24, respectively; An anti-1C10(0.5γ) antibody or an antigen-binding fragment thereof, wherein the anti-HIV-1 V3 antibody 1C10(0.5γ) comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 41 and 42, respectively.

5. An antibody that binds to the anti-HIV-1 V3 antibody 1C10(0.5γ) (anti-1C10(0.5γ) antibody) or an antigen-binding fragment thereof, the heavy chain variable region of the anti-1C10(0.5γ) antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:39; and the light chain variable region of the anti-1C10(0.5γ) antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 40; and wherein the heavy chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of SEQ ID NOs: 25, 26, and 27, respectively; and the light chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of SEQ ID NOs: 28, 29, and 30, respectively; An anti-1C10(0.5γ) antibody or an antigen-binding fragment thereof, wherein the anti-HIV-1 V3 antibody 1C10(0.5γ) comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 41 and 42, respectively.

6. The anti-1C10(0.5γ) antibody or its antigen-binding fragment according to any one of claims 1 to 5, wherein the anti-1C10(0.5γ) antibody is a full-length IgG antibody.

7. The anti-1C10(0.5γ) antibody or an antigen-binding fragment thereof according to any one of claims 1 to 6, wherein the antigen-binding fragment is a Fab fragment, a F(ab')2 fragment, an Fv fragment, or an scFv fragment.

8. The anti-1C10(0.5γ) antibody or its antigen-binding fragment according to any one of claims 1 to 7, which recognizes the antigen recognition region of the anti-HIV-1 V3 antibody 1C10(0.5γ).

9. A nucleic acid encoding any one of the anti-1C10(0.5γ) antibodies or antigen-binding fragments thereof according to any one of claims 1 to 8.

10. An expression vector comprising the nucleic acid of claim 9.

11. A transformant comprising the expression vector according to claim 10.

12. A detection agent for the anti-HIV-1 V3 antibody 1C10(0.5γ), comprising the anti-1C10(0.5γ) antibody or an antigen-binding fragment thereof according to any one of claims 1 to 8.

13. 1. A method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample, comprising: Contacting the sample with any of the anti-1C10(0.5γ) antibodies or antigen-binding fragments thereof according to any one of claims 1 to 8; and detecting the anti-HIV-1 V3 antibody 1C10(0.5γ) bound to the anti-1C10(0.5γ) antibody or antigen-binding fragment thereof according to any one of claims 1 to 8; Includes, a method.

14. The method of claim 13, wherein the detection is by a sandwich assay.

15. 15. The method of claim 13 or 14, wherein the detection is by enzyme-linked immunosorbent assay (ELISA) or electrochemiluminescence assay.

16. The capture antibody in the sandwich assay is any one of the anti-1C10(0.5γ) antibodies and antigen-binding fragments thereof according to any one of claims 1 to 8; The method according to claim 14, wherein the detection antibody in the sandwich assay is any of the anti-1C10(0.5γ) antibodies and antigen-binding fragments thereof described in any one of claims 1 to 8.

17. 1. A method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample, comprising: contacting the sample with any of the anti-1C10(0.5γ) antibodies or antigen-binding fragments thereof of claim 1; and detecting the anti-HIV-1 V3 antibody 1C10(0.5γ) bound to the anti-1C10(0.5γ) antibody or antigen-binding fragment thereof according to claim 2; Includes, a method.

18. 1. A method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample, comprising: Contacting the sample with any of the anti-1C10(0.5γ) antibodies or antigen-binding fragments thereof of claim 2; and detecting the anti-HIV-1 V3 antibody 1C10(0.5γ) bound to the anti-1C10(0.5γ) antibody or antigen-binding fragment thereof according to claim 1; Includes, a method.

19. 1. A method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample, comprising: contacting the sample with any of the anti-1C10(0.5γ) antibodies or antigen-binding fragments thereof of claim 1; and detecting the anti-HIV-1 V3 antibody 1C10(0.5γ) bound to the anti-1C10(0.5γ) antibody or antigen-binding fragment thereof according to claim 4; Includes, a method.

20. 1. A method for detecting anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample, comprising: Contacting the sample with any of the anti-1C10(0.5γ) antibodies or antigen-binding fragments thereof of claim 4; and detecting the anti-HIV-1 V3 antibody 1C10(0.5γ) bound to the anti-1C10(0.5γ) antibody or antigen-binding fragment thereof according to claim 1; Includes, a method.

21. 1. A method for determining the concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample, comprising: determining the concentration of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample by using the detection method according to any one of claims 13 to 20; A method comprising:

22. 1. A method for determining or monitoring the effectiveness of treatment with anti-HIV-1 V3 antibody 1C10(0.5γ) in a subject suffering from HIV-1 infection, comprising: Determining the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample from a subject previously administered with anti-HIV-1 V3 antibody 1C10(0.5γ) using the detection method according to any one of claims 13 to 20; and A method comprising the step of comparing the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a control sample with the level of anti-HIV-1 V3 antibody 1C10(0.5γ) in a sample from a subject.

Citation Information

Patent Citations

  • Anti-idiotypic antibodies that induce hiv-1 neutralizing antibodies

    JP2005517685A

  • Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies

    US20030100741A1

  • Anti-hiv monoclonal antibody

    WO2009066702A1